Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novartis refiles paperwork to FDA for novel cholesterol drug inclisiran

By Brian Buntz | July 6, 2021

Novartis
Novartis (NYSE: NVS) has resubmitted paperwork to the FDA for inclisiran, a subcutaneously-delivered drug candidate for treating hyperlipidemia in adults whose low-density lipoprotein cholesterol (LDL-C) remains elevated after taking a maximum tolerated dose of statin therapy.

In Dec. 2020, FDA issued a complete response letter (CRL) for inclisiran. A CRL indicates that the agency has decided not to approve a new drug application. In this case, FDA had expressed concern over unresolved inspection-related conditions at an Italian contract development and manufacturing organization (CDMO).

In a statement, Novartis announced that it plans to shift inclisiran production to its facility in Schaftenau, Austria. The company said it planned to move production of the drug to that plant before it received the CRL.

In its CRL, FDA did not relay concerns related to the safety or efficacy of inclisiran.

Novartis won EU approval for the drug in December.

RNAi therapeutics specialist Alnylam Pharmaceuticals first developed the drug, which the Medicines Company. Novartis completed the acquisition of the Medicines Company in early 2020.


Filed Under: clinical trials, Drug Discovery, Metabolic disease/endicrinology
Tagged With: CDMO, complete response letter, contract development and manufacturing organization, CRL, FDA, inclisiran, Medicines Company, Novartis
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50